Investigational Drug Information for Volixibat
✉ Email this page to a colleague
What is the drug development status for Volixibat?
Volixibat is an investigational drug.
There have been 5 clinical trials for Volixibat.
The most recent clinical trial was a Phase 1 trial, which was initiated on January 4th 2021.
The most common disease conditions in clinical trials are Cholangitis, Cholangitis, Sclerosing, and Non-alcoholic Fatty Liver Disease. The leading clinical trial sponsors are Mirum Pharmaceuticals, Inc., Shire, and [disabled in preview].
There are six US patents protecting this investigational drug and one hundred and fifty-four international patents.
Summary for Volixibat
| US Patents | 6 |
| International Patents | 154 |
| US Patent Applications | 33 |
| WIPO Patent Applications | 8 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2021-01-04) |
| Vendors | 19 |
Recent Clinical Trials for Volixibat
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis | Mirum Pharmaceuticals, Inc. | Phase 2 |
| A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With Intrahepatic Cholestasis of Pregnancy (OHANA) | Mirum Pharmaceuticals, Inc. | Phase 2 |
| A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC) | Mirum Pharmaceuticals, Inc. | Phase 2 |
Clinical Trial Summary for Volixibat
Top disease conditions for Volixibat
Top clinical trial sponsors for Volixibat
US Patents for Volixibat
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Volixibat | ⤷ Subscribe | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions | SATIOGEN PHARMACEUTICALS, INC. (San Diego, CA) | ⤷ Subscribe |
| Volixibat | ⤷ Subscribe | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions | SATIOGEN PHARMACEUTICALS, INC. (San Diego, CA) | ⤷ Subscribe |
| Volixibat | ⤷ Subscribe | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases | LUMENA PHARMACEUTIALS LLC (Lexington, MA) | ⤷ Subscribe |
| Volixibat | ⤷ Subscribe | Methods for treating cholestasis | MIRUM PHARMACEUTICALS, INC. (Foster City, CA) | ⤷ Subscribe |
| Volixibat | ⤷ Subscribe | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases | SHIRE HUMAN GENETIC THERAPIES, INC. | ⤷ Subscribe |
| Volixibat | ⤷ Subscribe | 1,4-benzothiepine 1,1-dioxide derivatives substituted by benzyl radicals, method for their preparation, pharmaceuticals comprising these compounds, and the use thereof | Sanofi-Aventis Deutschland GmbH (Frankfurt am Main, DE) | ⤷ Subscribe |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Volixibat
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Volixibat | European Patent Office | EP2575821 | 2030-05-26 | ⤷ Subscribe |
| Volixibat | European Patent Office | EP2995317 | 2030-05-26 | ⤷ Subscribe |
| Volixibat | European Patent Office | EP3593802 | 2030-05-26 | ⤷ Subscribe |
| Volixibat | Spain | ES2552657 | 2030-05-26 | ⤷ Subscribe |
| Volixibat | World Intellectual Property Organization (WIPO) | WO2011150286 | 2030-05-26 | ⤷ Subscribe |
| Volixibat | European Patent Office | EP2575821 | 2030-05-26 | ⤷ Subscribe |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
